MorphoSys AG (ETR:MOR) has been assigned a €85.00 ($100.00) price objective by equities researchers at Berenberg Bank in a report released on Thursday. The firm presently has a “buy” rating on the stock.

Other research analysts have also recently issued research reports about the company. J P Morgan Chase & Co set a €62.00 ($72.94) price target on MorphoSys AG and gave the stock a “neutral” rating in a research note on Friday, August 4th. Deutsche Bank AG set a €90.00 ($105.88) price target on MorphoSys AG and gave the stock a “buy” rating in a research note on Thursday, September 7th. Independent Research GmbH set a €77.00 ($90.59) price target on MorphoSys AG and gave the stock a “buy” rating in a research note on Thursday, September 7th. Goldman Sachs Group, Inc. (The) set a €55.00 ($64.71) price target on MorphoSys AG and gave the stock a “neutral” rating in a research note on Monday, July 24th. Finally, Commerzbank Ag set a €76.00 ($89.41) price target on MorphoSys AG and gave the stock a “buy” rating in a research note on Monday, July 24th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of €79.00 ($92.94).

Shares of MorphoSys AG (MOR) traded down 0.047% during midday trading on Thursday, hitting €73.974. The stock had a trading volume of 793 shares. The stock’s 50-day moving average is €69.48 and its 200-day moving average is €62.21. The stock’s market cap is €2.14 billion. MorphoSys AG has a 12 month low of €37.50 and a 12 month high of €75.45.

ILLEGAL ACTIVITY WARNING: “MorphoSys AG (MOR) Given a €85.00 Price Target at Berenberg Bank” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/22/morphosys-ag-mor-given-a-85-00-price-target-at-berenberg-bank.html.

About MorphoSys AG

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Analyst Recommendations for MorphoSys AG (ETR:MOR)

Receive News & Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related companies with MarketBeat.com's FREE daily email newsletter.